Stewart Abbot

USPTO Granted Patents = 15 (Patent Applications = 22)

CIPO Patents = 9 (Patent Applications = 6)

EPO Patents = 12 (Patent Applications = 28)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Warren, NJ (US) (2013 - 2019)
San Diego, CA (US) (2019 - 2023)

Company Filing History:

6 out of 64

Anthrogenesis Corporation

Antrhogenesis Corporation

patent

Years Active: 2013-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11806365 - Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis (2023-11-07),

2. 11512282 - Enhanced placental stem cells and uses thereof (2022-11-29),

3. 11130820 - Chimeric antigen receptors (2021-09-28),

4. 10967005 - Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis (2021-04-06),

5. 10329529 - Enhanced placental stem cells and uses thereof (2019-06-25),

6. 10238690 - Modified T lymphocytes comprising an inducible caspase and methods of apoptosis (2019-03-26),

7. 10150816 - Chimeric antigen receptors (2018-12-11),

8. 10041043 - Method of producing erythrocytes without feeder cells (2018-08-07),

9. 9763983 - Natural killer cells from placenta (2017-09-19),

10. 9255248 - Method of producing erythrocytes without feeder cells (2016-02-09),

11. 9254302 - Angiogenesis using placental stem cells (2016-02-09),

12. 9198938 - Amnion derived adherent cells (2015-12-01),

13. 8969315 - Enhancement of placental stem cell potency using modulatory RNA molecules (2015-03-03),

14. 8586360 - Method of producing erythrocytes without feeder cells (2013-11-19),

15. 8367409 - Amnion derived adherent cells (2013-02-05),

Title: The Innovative Contributions of Stewart Abbot

Introduction

Stewart Abbot is a prominent inventor based in Warren, NJ (US), known for his significant contributions to the field of biotechnology. With a total of 15 patents to his name, Abbot has made remarkable advancements in medical science, particularly in cancer treatment and stem cell research.

Latest Patents

Among his latest patents is the invention titled "Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis." This patent describes cells, specifically T cells, that express artificial cell death polypeptides, which induce cell death when multimerized or dimerized. This innovative approach has potential applications in treating diseases such as cancer. Another notable patent is "Enhanced placental stem cells and uses thereof," which presents placental stem cells that exhibit increased survival rates. This invention includes compositions comprising these enhanced placental stem cells and methods for their application in medical treatments.

Career Highlights

Stewart Abbot has worked with notable companies in the biotechnology sector, including Anthrogenesis Corporation and Celgene Corporation. His work in these organizations has contributed to the development of groundbreaking technologies and therapies.

Collaborations

Abbot has collaborated with esteemed colleagues in his field, including Xiaokui Zhang and Bitao Liang. These partnerships have fostered innovation and have been instrumental in advancing research in biotechnology.

Conclusion

Stewart Abbot's contributions to the field of biotechnology through his patents and collaborations highlight his role as a leading inventor. His work continues to impact medical science, particularly in the areas of cancer treatment and stem cell research.

This text is generated by artificial intelligence and may not be accurate.